EQS-News: Carl Zeiss Meditec with stable reve...

Margins and earnings fell sharply as revenue declined across key regions and businesses.

Risk flags

• ●Profitability risk is elevated, as adjusted EBITA margin fell from 11.1% to 8.0% and gross margin declined by 1.7 percentage points, reflecting both revenue pressure and rising costs.
• ●Regional and business unit concentration risk is evident, with Ophthalmology SBU and APAC region both posting significant declines (-4.8% and -8.7% respectively), which are not fully offset by growth elsewhere.
• ●Disclosure risk remains, as the company omits absolute figures for recurring revenue and order backlog, and provides no cash flow or balance sheet data, preventing a comprehensive assessment of liquidity or leverage.
• ●Execution risk is present in the company's forward-looking statements about integrating business units, optimizing the manufacturing footprint, and achieving medium-term margin recovery, as no concrete evidence of operational turnaround is provided.
• ●Impairment risk is explicit, with a €150m goodwill write-down in Ophthalmology expected in Q4, signaling that prior acquisitions or investments have underperformed and may further impact reported earnings.

Bottom line

This interim update signals clear operational and financial deterioration, with revenue, margins, and earnings all down year-on-year. The company is transparent about negative trends and does not attempt to spin the results, but the absence of key disclosures—such as cash flow, balance sheet, and absolute recurring revenue—limits a full risk assessment. Forward-looking guidance for the year is modest and does not imply a near-term turnaround, while the expected €150m goodwill impairment highlights further downside to reported earnings. Without evidence of sequential improvement or new commercial wins, the narrative remains weak and the investment case unconvincing. The most important takeaway is that margin pressure and regional weakness are persistent, and management’s operational adjustments have yet to translate into measurable financial recovery.

Announcement summary

(LSE/AIM:0DHC) Carl Zeiss Meditec AG reported revenue of around €1,553.7m in the first nine months of fiscal year 2025/26, compared to €1,600.1m in the prior year, representing a decline of -2.9% (adjusted for currency effects: 0.0%). Adjusted EBITA amounted to €124.5m (prior year: €177.0m), with an adjusted EBITA margin of 8.0% (prior year: 11.1%). The Ophthalmology SBU saw revenue decline by -4.8% to €1,191.4m, while the Microsurgery SBU increased revenue by +3.8% to €362.3m. The EMEA region achieved revenue growth of +5.4% to €509.0m, Americas revenue was €397.0m (-2.6%), and APAC revenue declined by -8.7% to €647.8m. Gross margin stood at 51.0% (prior year: 52.7%), and earnings per share amounted to €0.80 (prior year: €1.02). The company expects fiscal year 2025/26 revenue to reach around €2.15bn to €2.20bn, with an adjusted EBITA margin between 8% and 10%, and projects an impairment of goodwill of around €150m in the Ophthalmology SBU in Q4 2025/26.

Disagree with this article?